A detailed history of Foyston, Gordon, & Payne Inc transactions in Novartis Ag stock. As of the latest transaction made, Foyston, Gordon, & Payne Inc holds 23,856 shares of NVS stock, worth $2.72 Million. This represents 0.64% of its overall portfolio holdings.

Number of Shares
23,856
Previous 24,910 4.23%
Holding current value
$2.72 Million
Previous $2.41 Million 5.4%
% of portfolio
0.64%
Previous 0.6%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

SELL
$92.57 - $107.37 $97,568 - $113,167
-1,054 Reduced 4.23%
23,856 $2.54 Million
Q1 2024

May 07, 2024

SELL
$95.27 - $108.47 $52,017 - $59,224
-546 Reduced 2.14%
24,910 $2.41 Million
Q4 2023

Feb 07, 2024

BUY
$92.27 - $101.54 $1.4 Million - $1.54 Million
15,166 Added 147.39%
25,456 $2.57 Million
Q3 2023

Oct 26, 2023

SELL
$94.73 - $105.13 $9.73 Million - $10.8 Million
-102,752 Reduced 90.9%
10,290 $1.05 Million
Q2 2023

Aug 01, 2023

BUY
$92.52 - $104.91 $7.75 Million - $8.78 Million
83,712 Added 285.41%
113,042 $11.4 Million
Q1 2023

May 03, 2023

SELL
$80.03 - $92.81 $53,860 - $62,461
-673 Reduced 2.24%
29,330 $2.7 Million
Q4 2022

Feb 09, 2023

SELL
$75.55 - $92.52 $54,018 - $66,151
-715 Reduced 2.33%
30,003 $2.72 Million
Q3 2022

Nov 04, 2022

BUY
$74.61 - $87.26 $1.46 Million - $1.71 Million
19,546 Added 174.96%
30,718 $2.34 Million
Q2 2022

Aug 11, 2022

SELL
$80.52 - $93.75 $1.65 Million - $1.92 Million
-20,508 Reduced 64.73%
11,172 $2.69 Million
Q1 2022

Apr 27, 2022

BUY
$80.11 - $90.62 $2,803 - $3,171
35 Added 0.11%
31,680 $2.78 Million
Q4 2021

Feb 11, 2022

SELL
$79.7 - $88.13 $928,026 - $1.03 Million
-11,644 Reduced 26.9%
31,645 $2.77 Million
Q3 2021

Nov 12, 2021

SELL
$81.78 - $95.14 $18,809 - $21,882
-230 Reduced 0.53%
43,289 $3.54 Million
Q2 2021

Aug 06, 2021

SELL
$85.24 - $94.15 $1.1 Million - $1.21 Million
-12,854 Reduced 22.8%
43,519 $3.97 Million
Q1 2021

May 14, 2021

SELL
$83.5 - $98.47 $73,229 - $86,358
-877 Reduced 1.53%
56,373 $4.82 Million
Q4 2020

Feb 12, 2021

SELL
$78.07 - $94.43 $237,254 - $286,972
-3,039 Reduced 5.04%
57,250 $5.41 Million
Q3 2020

Nov 12, 2020

BUY
$82.14 - $91.0 $126,002 - $139,594
1,534 Added 2.61%
60,289 $5.24 Million
Q2 2020

Aug 14, 2020

SELL
$80.93 - $91.1 $962,014 - $1.08 Million
-11,887 Reduced 16.83%
58,755 $5.13 Million
Q1 2020

May 15, 2020

SELL
$70.67 - $99.01 $125,156 - $175,346
-1,771 Reduced 2.45%
70,642 $5.82 Million
Q4 2019

Feb 14, 2020

BUY
$84.35 - $95.37 $166,928 - $188,737
1,979 Added 2.81%
72,413 $6.86 Million
Q3 2019

Nov 14, 2019

SELL
$85.54 - $94.26 $866,776 - $955,136
-10,133 Reduced 12.58%
70,434 $6.12 Million
Q2 2019

Aug 15, 2019

BUY
$75.4 - $92.8 $1,734 - $2,134
23 Added 0.03%
80,567 $7.36 Million
Q1 2019

May 14, 2019

SELL
$75.32 - $86.15 $2,334 - $2,670
-31 Reduced 0.04%
80,544 $7.74 Million
Q4 2018

Feb 08, 2019

SELL
$73.66 - $82.02 $519,008 - $577,912
-7,046 Reduced 8.04%
80,575 $6.91 Million
Q3 2018

Nov 02, 2018

BUY
$66.94 - $77.43 $43,176 - $49,942
645 Added 0.74%
87,621 $7.55 Million
Q2 2018

Aug 10, 2018

BUY
$64.91 - $73.36 $183,046 - $206,875
2,820 Added 3.35%
86,976 $6.57 Million
Q1 2018

May 14, 2018

SELL
$70.39 - $84.15 $47,090 - $56,296
-669 Reduced 0.79%
84,156 $6.8 Million
Q4 2017

Feb 14, 2018

SELL
$72.33 - $77.64 $6 Million - $6.44 Million
-82,898 Reduced 49.43%
84,825 $7.12 Million
Q3 2017

Nov 14, 2017

BUY
$74.14 - $77.27 $5.98 Million - $6.24 Million
80,693 Added 92.72%
167,723 $14.4 Million
Q2 2017

Aug 14, 2017

BUY
N/A
87,030
87,030 $7.26 Million

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $245B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Foyston, Gordon, & Payne Inc Portfolio

Follow Foyston, Gordon, & Payne Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Foyston, Gordon, & Payne Inc, based on Form 13F filings with the SEC.

News

Stay updated on Foyston, Gordon, & Payne Inc with notifications on news.